Pipeline
Undisclosed
Oncology
IRAK1/IRAK4 Dual Inhibitors
In Silico
Synthesis
In vitro
In vivo
IRAK1 and IRAK4 are kinases involved in the innate immune response, mediating inflammatory signaling through the Toll-like receptor and interleukin-1 receptor pathways. Dysregulation of these kinases has been implicated in autoimmune diseases and certain cancers, including lymphomas and leukemias. The first round of molecular design for dual IRAK1/IRAK4 inhibitors has been completed, and preliminary hits have been identified through in vitro testing.
Undisclosed
Oncology
ATM and DNA-PK Inhibitors
In Silico
Synthesis
In vitro
In vivo
ATM (ataxia-telangiectasia mutated) and DNA-PK (DNA-dependent protein kinase) are key regulators of the DNA damage response, playing essential roles in the repair of double-strand breaks. Mutations or overactivity of these proteins are associated with cancer development and resistance to DNA-damaging therapies. Molecules targeting ATM and DNA-PK have been designed and tested on proteins and in cell culture systems.
Undisclosed
Oncology
Irisine Modulators
In Silico
Synthesis
In vitro
In vivo
Irisine is a hormone-like myokine released from muscle tissue during exercise, involved in energy metabolism and the browning of adipose tissue. Altered irisine signaling has been linked to metabolic disorders such as obesity and type 2 diabetes, and is being explored in the context of metabolic syndrome-related diseases. Hit identification for irisine modulators is currently in progress.
Target
Pathway
Indication
Pre-clinical stage
Undisclosed
IRAK1/IRAK4 Dual Inhibitors
Oncology
In Silico
Synthesis
In vitro
In vivo
IRAK1 and IRAK4 are kinases involved in the innate immune response, mediating inflammatory signaling through the Toll-like receptor and interleukin-1 receptor pathways. Dysregulation of these kinases has been implicated in autoimmune diseases and certain cancers, including lymphomas and leukemias. The first round of molecular design for dual IRAK1/IRAK4 inhibitors has been completed, and preliminary hits have been identified through in vitro testing.
Undisclosed
ATM and DNA-PK Inhibitors
Oncology
In Silico
Synthesis
In vitro
In vivo
ATM (ataxia-telangiectasia mutated) and DNA-PK (DNA-dependent protein kinase) are key regulators of the DNA damage response, playing essential roles in the repair of double-strand breaks. Mutations or overactivity of these proteins are associated with cancer development and resistance to DNA-damaging therapies. Molecules targeting ATM and DNA-PK have been designed and tested on proteins and in cell culture systems.
Undisclosed
Irisine Modulators
Oncology
In Silico
Synthesis
In vitro
In vivo
